Your browser doesn't support javascript.
loading
XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL.
Wang, Naitao; Hakimi, A Ari; Chen, Yu.
Affiliation
  • Wang N; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hakimi AA; Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Chen Y; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res ; 28(21): 4600-4602, 2022 11 01.
Article in En | MEDLINE | ID: mdl-35984355
Through analysis of the cancer dependency map of CRISPR and short hairpin RNA datasets, the antiapoptotic BCL-XL was found to be a selective dependency in kidney cancer. Among kidney cancers, BCL-XL inhibition is most active in those with a mesenchymal gene signature, which portends a poor prognosis and response to current therapies. See related article by Grubb et al., p. 4689.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Apoptosis / Kidney Neoplasms Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Apoptosis / Kidney Neoplasms Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: United States